PTC Therapeutics (PTCT) Misses Q3 EPS by 22c, Revenue Beats

PTC Therapeutics (NASDAQ: PTCT) reported Q3 EPS of ($1.53), $0.22 worse than the analyst estimate of ($1.31). Revenue for the quarter came in at $217.1 million versus the consensus estimate of $178.9 million.

For earnings history and earnings-related data on PTC Therapeutics (PTCT) click here.

You May Also Be Interested In

• Micron offers Taiwan workers up to 68-month bonuses as strike threat looms
• Brinker Int'l (EAT) PT Lowered to $240 at DA Davidson Ahead of Analyst Day
• GE Vernova (GEV) PT Raised to $1,185 at Jefferies